GE HealthCare Technologies Inc. (GEHC)
SEC filings, insider trading & institutional ownership from EDGAR.
GE HealthCare Technologies Inc. is a global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians diagnose and treat complex diseases. It employs approximately 54,000 people and has served patients and providers for nearly 130 years. Revenue comes from the sale of medical devices, consumable products, service capabilities, and AI-enabled cloud and software solutions. The company was spun off from the General Electric Company (now GE Aerospace) on January 3, 2023, and is a Delaware corporation headquartered in Chicago, Illinois.
The business is organized into four segments. Imaging covers Molecular Imaging (cyclotrons, PET/CT, SPECT, PET/MR and nuclear medicine), Computed Tomography, Magnetic Resonance, Women's Health (mammography, biopsy positioning and bone densitometry), and X-ray (fixed, mobile and fluoroscopy), along with AI-enabled software and services. Advanced Visualization Solutions offers Specialized Ultrasound (Comprehensive Care and Women's Health) and Procedural Guidance (CardioVascular and Interventional Solutions, and Surgical Innovations such as mobile surgical C-arms). Patient Care Solutions covers Patient Monitoring, Diagnostic Cardiology (ECG), Maternal Infant Care, Anesthesia, consumables, and digital solutions. Pharmaceutical Diagnostics supplies contrast media and radiopharmaceutical imaging agents, plus contrast injection devices offered through collaborations with third-party manufacturers. Its agents also work with other vendors' imaging systems.
Customers are hospitals, health systems, and researchers, including public, private, academic, and government institutions, in over 160 countries. The company sells through a multi-channel model of about 9,700 sales professionals and over 5,000 indirect third-party partners, including inside sales, field sales, agents, distributors, and virtual sales teams. About 8,900 field service engineers support the installed base, with service offerings ranging from preventative maintenance to onsite biomedical engineering contracts. Results vary by quarter, and the fourth quarter has historically been the strongest because of customer spending patterns.
GE HealthCare manufactures, assembles, and produces pharmaceuticals in 44 facilities across 17 countries, using a globally managed sourcing and distribution network with regionally focused facilities. Its supply chain emphasizes resilience through buffer capacity and diversified sourcing and manufacturing. About 11,100 engineers and scientists work on R&D, including collaborations with academic institutions and medical centers. The company relies on patents, trademarks, copyrights, trade secrets, and confidentiality agreements to protect its intellectual property. Its primary global competitors include Siemens Healthineers, Philips Healthcare, United Imaging, Mindray, and Canon, and in Pharmaceutical Diagnostics, Bayer, Bracco, Guerbet, and Curium. The company also competes and partners with digital health and healthcare AI participants.
AI-summarized from Item 1 (Business) of the company’s most recent 10-K filing.
Financials
As reported to the SEC via XBRL, no adjustments
| Gross profit | $8.25B |
| Operating income | $2.76B |
| Diluted EPS | $4.55 |
| Gross margin | 40.0% |
| Net margin | 10.1% |
Latest filings
10-K, 10-Q, 8-K, Form 4 & 13D/G. Sourced directly from SEC EDGAR
| Form | Filed | Accession |
|---|---|---|
| 8-K | Nov 5, 2026 | 0001932393-26-000063EDGAR |
| 10-Q | Oct 28, 2026 | 0001932393-26-000059EDGAR |
| 8-K | Oct 28, 2026 | 0001932393-26-000058EDGAR |
| 8-K | Sep 22, 2026 | 0001932393-26-000053EDGAR |
| 4Grogan William K | Sep 16, 2026 | 0001694002-26-000011EDGAR |
| 4Rackliffe Philip | Sep 4, 2026 | 0002027284-26-000013EDGAR |
| 4O'Neill Kevin Michael | Sep 4, 2026 | 0001951605-26-000008EDGAR |
| 4Newcomb George A. | Sep 4, 2026 | 0001952158-26-000008EDGAR |
Insider trading
From Form 4 filings
| Insider | Date | Type |
|---|---|---|
| Grogan William K | Sep 14, 2026 | Grant / award |
| Arduini Peter J | Sep 3, 2026 | Tax withholding |
| Estrampes Catherine | Sep 3, 2026 | Tax withholding |
| Holton Adam Y | Sep 3, 2026 | Tax withholding |
| Jimenez Frank R | Sep 3, 2026 | Tax withholding |
Top holders
13F & 13D/G • latest quarter
| Holder | Stake | Filed | Value |
|---|---|---|---|
| Dodge & Cox | 8.4% | Aug 13, 2026 | $2.42B |
| BlackRock, Inc. | 8.3% | Aug 7, 2026 | $2.4B |
| Vanguard Capital Management | 6.6% | Aug 13, 2026 | $1.9B |
| STATE STREET CORPORATION | 4.6% | Sep 22, 2026 | $1.34B |
| Vanguard Portfolio Management | 4.5% | Aug 13, 2026 | $1.3B |
GEHC's filings are public. The insight is one click away.
Scrutar's AI reads every GEHC filing and points out what matters. Red flags, risk shifts, disclosure quality and key relationships. Cited to the source, free with an account.
Never miss a GEHC filing.
Get an email when GEHC files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 8, 2026Source: SEC EDGAR.